Soufflé Therapeutics
Soufflé Therapeutics is a genetic medicine company developing nucleic acid (siRNA) therapeutics that use proprietary cell-specific ligand-conjugation technology to target and deliver treatments to specific cell types. Its initial programs address muscle and heart disorders, with first therapies targeting Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies, with clinical trials expected to begin in 2026. The company is headquartered in Watertown, Massachusetts and was surfaced through the API Evangelist network as a portfolio company of Bessemer Venture Partners. It is a therapeutics/pharmaceutical company and publishes no public API, developer portal, or SDK surface.
Soufflé Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Therapeutics, Genetic Medicine, and siRNA.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API